Bio-Rad Laboratories, Inc. (NYSE:BIO) Q2 2021 Earnings Conference Call July 29, 2021 6:00 PM ET
Company Participants
Edward Chung - Head of IR
Norman Schwartz - CEO
Ilan Daskal - EVP and CFO
Andrew Last - EVP and COO
Annette Tumolo - President, Life Science Group
Dara Wright - President, Clinical Diagnostics Group
Conference Call Participants
Patrick Donnelly - Citi
Brandon Couillard - Jefferies
Dan Leonard - Wells Fargo
Jack Meehan - Nephron Research
Operator
Good afternoon, ladies and gentlemen, and welcome to the Q2, 2021 Bio-Rad Laboratories, Inc. Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions]
I would now like to turn the conference over to your host, Mr. Edward Chung, Head of Investor Relations. Sir, please go ahead.
Edward Chung
Thank you, Joanna. Good afternoon and thank you all for joining us. Today, we will review the second quarter 2021 financial results and provide an update on key business trends for Bio-Rad with me on the phone today are Norman Schwartz, our Chief Executive Officer; Ilan Daskal, Executive Vice President and Chief Financial Officer; Andy Last, Executive Vice President and Chief Operating Officer; Annette Tumolo, President of the Life Science Group; and Dara Wright, President of the Clinical Diagnostics Group.
Before we begin our review, I'd like to caution everyone that we will be making forward-looking statements about management's goals, plans, expectations, our future financial performance and other matters. These statements are based on assumptions and expectations of future events that are subject to risks and uncertainties. Included in these forward-looking statements are commentary, regarding the impact of the COVID 19 pandemic on Bio-Rad’s results, operations and steps Bio-Rad is taking in response to the pandemic.
- Read more current BIO analysis and news
- View all earnings call transcripts